Covid-19 Resources for Physicians
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2
The US Centers for Disease Control and Prevention lists asthma as a risk factor for severe COVID-19 illness, which is logical given that many respiratory viruses have been well established to cause more serious illnesses in those with chronic airway diseases such as asthma. However, asthma and respiratory allergy have not been identified as significant risk factors for severe COVID-19 illness in case series from China. These preliminary reports led us to question whether we could identify features of allergy and/or asthma that could be associated with potential for reduced severity of COVID-19 illness.
Read more »
COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic:
In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services.
Read more »
ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—implications for COVID-19
Coronavirus disease 2019 (COVID-19) is caused by a novel zoonotic coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been identified as a pandemic by the World Health Organization. Several risk factors have been identified for severe COVID-19–associated pneumonia including increased age and the presence of comorbidities, in particular diabetes, cardiovascular disease, and tobacco smoking. However, a number of reports have failed to identify excess risk in patients with respiratory airway diseases such as asthma.
Read more »
A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services
With rates of new infections and fatalities potentially reaching a plateau and/or declining, restrictions on provision of routine ambulatory care are lifting, and there is a need to help guide the allergy/immunology clinician on how to reinitiate services. Given the fact that coronavirus disease 2019 will circulate within our communities for months or longer, we present a flexible, algorithmic best-practices planning approach on how to prioritize services, in 4 stratified phases of reopening according to community risk level, as well as highlight key considerations for how to safely do so.
Read more »
Last updated: Dec 2, 2021
This COVID-19 information may vary and will be updated depending upon current situations. As there is yet much to learn about COVID-19, please be advised that the materials and other information provided by this website are for information purposes only and are not intended to replace or constitute the giving of medical advice or treatments.
The Canadian Society of Allergy and Clinical Immunology (CSACI) intends that the information contained in this site to be accurate. However, errors sometimes occur. Therefore, CSACI disclaims any warranty of any kind, whether express or implied, as to any matter whatsoever relating to this service. In no event shall CSACI be liable for any indirect, special, incidental or consequential damages arising out of use of or reliance on any content or materials contained herein.
The CSACI does not assume and it hereby disclaims any and all liability to any person or entity for any claims, damages, liability or loss (including, without limitation, any liability for injury or other damage resulting from any use of or any reliance on this service or from the posting of any content or material by any third party. No use of, reliance on, any materials included in this site shall be deemed to give rise to a physician-patient relationship. No material included in this site shall be deemed to present the only or necessarily the best method or procedure with respect to a matter discussed on this service; rather, any such material shall be acknowledged as only the approach or opinion of the discussant. The users assume all risks of using the materials included in this site.